User profiles for E. Reimann

Eric Reiman

Banner Alzheimer's Institute
Verified email at bannerhealth.com
Cited by 87604

The trichothecenes and their biosynthesis

JF Grove, E Reimann, S Roy, JF Grovey - Progress in the Chemistry of …, 2007 - Springer
The trichothecenes are a group of naturally-occurring sesquiterpenoid epoxides which
show a broad range of biological activity. They are powerful inhibitors of eukaryotic protein …

The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core

…, SM Landau, CA Mathis, JC Price, EM Reiman… - Alzheimer's & …, 2010 - Elsevier
BACKGROUND: This is a progress report of the Alzheimer's Disease Neuroimaging Initiative
(ADNI) positron emission tomography (PET) Core. METHODS: The Core has supervised …

Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis

…, RP Mayeux, E McDade, S Moreno, EM Reiman… - Neurology, 2014 - AAN Enterprises
… Kaplan-Meier curves representing survival to symptom onset are shown in figure e-1. For
all mutation carriers, median survival to symptom onset was 47 years (95% confidence interval …

Purification and properties of rabbit skeletal muscle adenosine 3', 5'-monophosphate-dependent protein kinases

EM Reimann, DA Walsh, EG Krebs - Journal of Biological Chemistry, 1971 - ASBMB
A modified procedure for purification of the adenosine 3',5'-monophosphate-dependent (cyclic
AMP-dependent) protein kinase from rabbit skeletal muscle is described. This procedure …

[HTML][HTML] The yeast GLC7 gene required for glycogen accumulation encodes a type 1 protein phosphatase.

…, ZY Peng, KK Schlender, EM Reimann… - Journal of Biological …, 1991 - Elsevier
The glc7 mutant of the yeast Saccharomyces cerevisiae does not accumulate glycogen due
to a defect in glycogen synthase activation (Peng, Z., Trumbly, RJ, and Reimann, EM (1990) …

Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on …

…, DC Park, EM Reiman, CC Rowe, E Siemers… - Alzheimer's & …, 2011 - Elsevier
… FDG-PET) or functional magnetic resonance imaging (fMRI), with a dashed line to indicate
that synaptic dysfunction may be detectable in carriers of the ɛ4 allele of the apolipoprotein E

Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease

…, ER Martin, MI Kamboh, AJ Saykin, EM Reiman… - Nature …, 2011 - nature.com
The Alzheimer Disease Genetics Consortium (ADGC) performed a genome-wide association
study of late-onset Alzheimer disease using a three-stage design consisting of a discovery …

[41] Assay of cyclic AMP-dependent protein kinases

JD Corbin, EM Reimann - Methods in enzymology, 1974 - Elsevier
Publisher Summary Most tissues contain protein kinases that are stimulated several-fold by
cyclic 3', 5'-adenosine monophosphate (cAMP) and catalyze the transfer of phosphate from …

Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing

…, F Salani, A Ciaramella, E Boerwinkle, EM Reiman… - Nature …, 2019 - nature.com
Risk for late-onset Alzheimer’s disease (LOAD), the most prevalent dementia, is partially
driven by genetics. To identify LOAD risk loci, we performed a large genome-wide association …

APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline

…, JM Ringman, LS Schneider, JC Morris, EM Reiman… - Nature, 2020 - nature.com
… The E4 variant of apolipoprotein E (APOE4), the main susceptibility gene for Alzheimer’s
disease 11 , 12 , 13 – 14 , leads to accelerated breakdown of the BBB and degeneration of …